Please wait while the formulary information is being retrieved.
LAGEVRIO (EUA) (molnupiravir)
Lagevrio 200 mg capsule (EUA)
- 4 capsules (800 mg) by oral route every 12 hours for 5 days
Default screening record
- 4 capsules (800 mg) by oral route every 12 hours for 5 days
- None
Contraindicated
- None
Severe
Moderate
- None
- Lactation
Contraindicated
- Pregnancy
Severe
Moderate
- None
LAGEVRIO (EUA) (molnupiravir)
- None
- None
More Frequent
Severe
Less Severe
- None
- None
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- Abnormal hepatic function tests
- Angioedema
- Hypersensitivity drug reaction
Less Severe
- Diarrhea
- Dizziness
- Erythema
- Nausea
- Skin rash
- Urticaria
Contraindicated
None
Severe Precaution
Molnupiravir
Possible risk of bone and cartilage toxicity based on animal data; safety and effectiveness not established in pediatric patients < 18 years.
- 1 Day – 18 Years
- Possible risk of bone and cartilage toxicity based on animal data; safety and effectiveness not established in pediatric patients < 18 years.
Management or Monitoring Precaution
None
Molnupiravir
- Severity Level:
D
- Additional Notes: Manufacturer does not recommend during pregnancy
Contraindicated
Molnupiravir
Insuff human data; mfr does not rec during tx and for 4 days after last dose
| General | Excretion Potential | Effect on Infant | Notes |
| Drug should not be given to breast feeding mothers | Unknown | Not known; no or inclusive data | Insuff human data; mfr does not rec during tx and for 4 days after last dose |
Precaution Exists
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
No Known Risk
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Contraindicated
None
Precaution Exists
None
No Known Risk
None
- None
Formulary Reference Tool